Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Dec 25:9:1-3.
doi: 10.1016/j.jdcr.2020.12.021. eCollection 2021 Mar.

Treatment of cutaneous sarcoidosis with tofacitinib 2% ointment and extra virgin olive oil

Mariam Alam  1 , Victoria Fang  2 , Misha Rosenbach  2
Affiliations
Case Reports

Treatment of cutaneous sarcoidosis with tofacitinib 2% ointment and extra virgin olive oil

Mariam Alam et al. JAAD Case Rep. .
No abstract available

Keywords: EVOO, extra virgin olive oil; IFN, interferon; JAK inhibitor; JAK, Janus kinase; JAK-STAT; STAT, signal transducer and activator of transcription; cutaneous sarcoidosis; oleocanthal; olive oil; tofacitinib.

PubMed Disclaimer

Conflict of interest statement

Dr Rosenbach receives research support from Processa and has received consulting fees from Merck, Janssen, and Lilly. Drs Alam and Fang have no conflicts of interest to declare.

Figures

Fig 1
Fig 1
Scalp at presentation, before treatment. Violaceous, atrophic, scaly patches and thin plaques with crusted nodule at center of scalp.
Fig 2
Fig 2
Cutaneous sarcoidosis before and after tofacitinib 2% ointment and extra virgin olive oil applied to the scalp. A, Violaceous, scaly plaques on the scalp; Cutaneous Sarcoidosis Activity Morphology Instrument activity score 9: inflammation (3), induration (1), surface change (1), area (4). B, Improvement in lesions on the scalp after 5 months of intermittent topical tofacitinib. Cutaneous Sarcoidosis Activity Morphology Instrument activity score 5: inflammation (1), induration (0), surface change (0), area (4).
See this image and copyright information in PMC

References

    1. Damsky W., Thakral D., McGeary M.K., Leventhal J., Galan A., King B. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. J Am Acad Dermatol. 2020;82(3):612–621. - PMC - PubMed
    1. Wei J.J., Kallenbach L.R., Kreider M., Leung T.H., Rosenbach M. Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera. JAAD Case Rep. 2019;5(4):360–361. - PMC - PubMed
    1. Damsky W., Thakral D., Emeagwali N., Galan A., King B. Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis. N Engl J Med. 2018;379(26):2540–2546. - PMC - PubMed
    1. Damsky W., Singh K., Galan A., King B. Treatment of necrobiosis lipoidica with combination janus kinase inhibition and intralesional corticosteroid. JAAD Case Rep. 2020;6(2):133–135. - PMC - PubMed
    1. Lee J., English J.C. Improvement in ulcerative necrobiosis lipoidica after janus kinase-inhibitor therapy for polycythemia vera. JAMA Dermatol. 2018;154(6):733–734. - PubMed

Publication types

LinkOut - more resources